InvestorsHub Logo
Followers 1
Posts 307
Boards Moderated 0
Alias Born 07/24/2015

Re: jessellivermore post# 56156

Tuesday, 08/11/2015 5:30:00 PM

Tuesday, August 11, 2015 5:30:00 PM

Post# of 430369
JL,

I think I failed to fully develop my thoughts on that post. I agree 100% Amarin can negate the risks by letting the FDA screen materials in advance, and that permitting proactive truth/non-misleading communication is better for society.

However, if FDA claimed it was a misleading study or that it's intended use by Amarin was misleading, I think things might be a bit messy for Amarin to be allowed to communicate it, particularly if it is after a final ruling is issued for the case. Would Judge E reopen the case? would a new case be brought? I don't think it's a likely or important scenario, but I'm entertaining all possibilities.

As an aside, I want to thank you and all the other heavy-hitters on this board for your hard work and critical thinking. I'm just a young punk, but I've been in the biotech game for 8 years now (starting with DSCO, *shudders*), and I've learned more in the last few months here than I have from any other board (YMB aka the stock-slums) or book.

And on that note, does anyone have any good investing/finance books to recommend?

I've covered most of the 'basics' (Intelligent Investor, Random Walk Down WS, etc). Maybe something with some biotech flavor?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News